DIAPH3 and glioblastoma: We previously observed that continuous pharmacological mDia2 activation with the small-molecule intramimic agonist IMM02 triggers a mesenchymal-to-amoeboid transition in invading patient-derived Pat9 GBM spheres that is associated with inhibition of new tumor microtube formation, loss of existing tumor microtubes, and a block of invasion [12].